isotretinoin and Neurofibroma--Plexiform

Selumetinib is a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor (MEKi) approved to treat inoperable plexiform neurofibromas and used off-label for low-grade gliomas. Acneiform eruptions are a known complication of MEKi use, and in some cases, may lead to paused, dose-reduced, or discontinued therapy. Isotretinoin has been reported as an effective treatment for acneiform eruptions secondary to targeted therapies, primarily in the adult population. Here we describe a pediatric patient with a severe acneiform eruption secondary to selumetinib who was successfully treated with low-dose isotretinoin when unresponsive to conventional therapies.

Topics: Acneiform Eruptions; Child; Humans; Isotretinoin; Mitogen-Activated Protein Kinase Kinases; Neurofibroma, Plexiform; Protein Kinase Inhibitors